This episode is an interview with Dr. Wouter Vaes, the Chief Science Officer of Peregrion. We discuss how accelerator mass spectrometry is being used in early clinical development for drug metabolism and pharmacokinetics. We discuss using this technology to support development of oncology agents, determining absolute bioavailability without IV toxicology work, and more.

Links discussed in the show:

• You can contact Wouter by email: wouter.vaes@peregrion.com
• Connect with Peregrion on LinkedIn or their website
• Symposium on microtracer studies
• FDA guidance on safety testing of drug metabolites
• White paper on human ADME data
• You can connect with Nathan on LinkedIn and send me a message
• Send Nathan a message
• Sign up for Nathan’s newsletter

Copyright Teuscher Solutions LLC

All Rights Reserved